A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses

A technology of immunogenicity and composition, applied in the field of vaccine preparations with combined adjuvants, which can solve the problems of inability to induce protective immune responses

Inactive Publication Date: 2017-10-13
THEVAX GENETICS VACCINE
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most existing vaccines contain only a single adjuvant
Due to its limitations, neither adjuvant can induce the full protective immune response required for various vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses
  • A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses
  • A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0131] The following provides exemplary instruments, devices, methods and related results according to the embodiments of the present invention, but does not constitute a limitation to the scope of the present invention. It should be understood that headings or subtitles may be included in the examples for ease of reading, which should not limit the scope of the present invention. In addition, specific theories are presented and disclosed below, however, no matter whether they are right or wrong, any specific theory or action plan should not limit the scope of the present invention as long as the practice of the present invention is not affected.

[0132] Immunogenic protein preparation:

[0133] Immunogenic proteins were expressed in E. coli expression system. It may be antigen alone, or an antigen and ER retention signal (K3) fused to P. aeruginosa exotoxin A domains I and II (i.e., PE 407 ) to the C-terminus to generate PE 407 -(antigen)-K3 fusion protein, or fusion to R...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.

Description

technical field [0001] The present invention relates generally to vaccine formulations, and more particularly to vaccine formulations with combined adjuvants. Background technique [0002] Adjuvants are key components of many vaccines. Most existing vaccines contain only a single adjuvant. Due to its limitations, neither adjuvant can induce all the protective immune responses required for various vaccines. Therefore, techniques for including various adjuvants in vaccine formulations need to be sought. Contents of the invention [0003] In one aspect, the invention relates to a vaccine composition comprising: [0004] (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; [0005] (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A and QS-21; and [0006] (c) Toll-like receptor agonist adjuvant [Toll-like receptor (TLR) agonist adjuvant], which is selected from the group consisting o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/12A61K39/21A61K39/145A61K47/42A61P31/20A61P31/18A61P31/16
CPCA61K2039/545C12N2710/20034A61K38/164A61K38/1774A61K39/12A61K39/39A61K2039/55511A61K2039/55561A61K2039/55572A61K2039/55577A61K2039/585A61K2039/6031A61K2039/6037C12N2710/20071A61P31/12A61P31/14A61P31/16A61P31/18A61P31/20A61P35/00A61P37/04A61P43/00Y02A50/30C12N7/00C12N2710/20033
Inventor 吴嘉茂吴俊明邱怡翠林吟璟庄贤凯谢馥檀陈冠铭
Owner THEVAX GENETICS VACCINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap